Search

Your search keyword '"Mikael Chetboun"' showing total 4 results
Start Over Author "Mikael Chetboun" Publisher hal ccsd
4 results on '"Mikael Chetboun"'

1. Erratum. Ten-Year Outcome of Islet Alone or Islet After Kidney Transplantation in Type 1 Diabetes: A Prospective Parallel-Arm Cohort Study. Diabetes Care 2019;42:2042-2049

Author

Eric Van Belle, François Machuron, Marc Hazzan, Marie-Christine Vantyghem, Christian Noel, Thomas Hubert, Robert Caiazzo, Stéphanie Espiard, Julie Kerr-Conte, Arnaud Jannin, Violeta Raverdy, Pascal Pigny, François Pattou, Nathalie Delalleau, Valery Gmyr, Kristell Le Mapihan, Marie Frimat, Mikael Chetboun, Université de Lille, LillOA, Recherche translationnelle sur le diabète - U 1190 (RTD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université de Lille, Miniaturisation pour la Synthèse, l’Analyse et la Protéomique - UAR 3290 (MSAP), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Miniaturisation pour la Synthèse, l’Analyse et la Protéomique - USR 3290 (MSAP), Institut de Chimie du CNRS (INC)-Université de Lille-Centre National de la Recherche Scientifique (CNRS), Inserm, CHU Lille, Recherche translationnelle sur le diabète (RTD) - U1190, Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277, Centre Hospitalier Régional Universitaire [Lille] [CHRU Lille], Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (EGID) - U1011, Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 [RID-AGE], Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD], Miniaturisation pour la Synthèse, l’Analyse et la Protéomique - UAR 3290 [MSAP], Lille Inflammation Research International Center - U 995 [LIRIC], and Recherche translationnelle sur le diabète - U 1190 [RTD]

Subjects
Advanced and Specialized Nursing, Type 1 diabetes, medicine.medical_specialty, geography, geography.geographical_feature_category, business.industry, Endocrinology, Diabetes and Metabolism, [SDV]Life Sciences [q-bio], MEDLINE, 030209 endocrinology & metabolism, medicine.disease, Islet, 3. Good health, Islet after kidney, Transplantation, [SDV] Life Sciences [q-bio], 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, 030212 general & internal medicine, business, Cohort study
Abstract

The names of the working groups that collaborated in the study reported in this article were inadvertently omitted from the byline. The corrected byline should … 2019;42

Published
2020
Full Text
View/download PDF

2. Portal Inflow Modulation by Somatostatin After Major Liver Resection: A Pilot Study

Author

Tullio Piardi, Patrick Pessaux, T. Lestra, Rami Rhaiem, Reza Kianmanesh, Mikael Chetboun, Riccardo Memeo, Daniele Sommacale, Institut de Recherche sur les Maladies Virales et Hépatiques (IVH), and Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
medicine.medical_specialty, Portal vein, Liver Failure/prevention and control, Pilot Projects, macromolecular substances, Gastroenterology, Resection, Regional Blood Flow/drug effects, 03 medical and health sciences, Postoperative Complications, 0302 clinical medicine, Internal medicine, hemic and lymphatic diseases, Hepatectomy/*adverse effects/methods, medicine, Hepatectomy, Humans, Cardiovascular Agents/*therapeutic use, Portal Vein, business.industry, technology, industry, and agriculture, Cardiovascular Agents, Portal Pressure, Postoperative Complications/prevention and control, 3. Good health, Somatostatin/*therapeutic use, Somatostatin, Portal Vein/physiology, Regional Blood Flow, Hepatic parenchyma, 030220 oncology & carcinogenesis, Portal Pressure/*drug effects, 030211 gastroenterology & hepatology, Surgery, business, Liver Failure, Major hepatectomy, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Major hepatectomy (MH) can lead to an increasing portal vein pressure (PVP) and to lesions of the hepatic parenchyma. Several reports have assessed the deleterious effect of a high posthepatectomy PVP on the postoperative course of MH. Thus, several surgical modalities of portal inflow modulation (PIM) have been described. As for pharmacological modalities, experimental studies showed a potential efficiency of Somatostatin to reduce PVP and flow. To our knowledge, no previous clinical reports of PIM using somatostatin are available. Herein, we report the results of PIM using somatostatin in 10 patients who underwent MH with post-hepatectomy PVP > 20 mmHg. Our results suggest Somatostatin could be considered as an efficient reversible PIM when PVP decrease is above 2.5 mmHg.

Published
2018
Full Text
View/download PDF

3. Liver Double-Tightened Maneuver: Optimal Outflow Control During Liver Parenchymal Transection of the Right and Left Hepatectomies

Author

Tullio Piardi, Patrick Pessaux, Reza Kianmanesh, Sara Cavallari, Rami Rhaiem, Mikael Chetboun, Daniele Sommacale, Institut de Recherche sur les Maladies Virales et Hépatiques (IVH), and Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Male, Liver Diseases/*surgery, 030230 surgery, Hepatic Veins, Right gastric vein, 03 medical and health sciences, 0302 clinical medicine, Parenchyma, 80 and over, Medicine, Hepatectomy, Humans, Hepatectomy/*methods, Aged, Aged, 80 and over, Right hepatic vein, business.industry, Liver Diseases, Hepatic Veins/*surgery, Anatomy, Middle Aged, Liver/blood supply/*surgery, Treatment Outcome, Liver, 030220 oncology & carcinogenesis, Surgery, Outflow, Female, Anterior approach, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Published
2017
Full Text
View/download PDF

4. European experience of 573 liver resections for hepatocellular adenoma: a cross-sectional study by the AFC-HCA-2013 study group

Author

Daniel Sommacale, Emilie Bollon, Bernard Pol, François-René Pruvot, Marie Castagnet, Yves Patrice Le Treut, Alexandre Filippello, Jacques Belghiti, Frédéric Borie, Lorenzo Capussotti, Pierre Allemann, Guido Torzilli, Alexis Laurent, Daniel Cherqui, Philippe Bachellier, Gilles Mentha, Olivier Scatton, Mustapha Adham, Bertrand Suc, Olivier Turrini, Reza Kiamanesh, Jean Hardwigsen, Marco Montorsi, Romain Riboud, Fabrice Muscari, Benjamin Darnis, Patrice Pessaux, Olivier Farges, Olivier Soubrane, Mathieu Gonot-Gachard, Jean Yves Mabrut, Safi Dokmak, Jean-Charles Nault, Manuela Cesaretti, Pietro Addeo, Laura Ornella Perotto, Jean Marc Régimbaud, Nicolas Demartines, Alexandra Dili, Irinel Popescu, Jean Robert Delpero, Ahmet Ayav, Mikael Chetboun, Emmanuel Boleslawski, Jean luc Porcheron, Jean Michel Fabre, Christian Letoublon, Ricardo Gauzolino, Service de chirurgie digestive, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Service de chirurgie hepato-pancreato-biliaire, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Jean Verdier [AP-HP], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Département d'hépato-gastroentérologie, CHU Grenoble-Université Grenoble Alpes (UGA), CHU Strasbourg, Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Hôpital de la Timone [CHU - APHM] (TIMONE), Service de Chirurgie Digestive Hépatobiliaire et Endocrine [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Chirurgie Générale et Digestive [Rangueil], CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Centre hépato-biliaire (CHB), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor, Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon, Hôpital Jean Verdier [Bondy], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, and UCL - (MGD) Service de chirurgie

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Time Factors, Adenoma, Cross-sectional study, Hemorrhage, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, Liver resections, Gastroenterology, Adenoma, Liver Cell, Malignant transformation, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Internal medicine, Hepatectomy, Humans, Medicine, Retrospective Studies, Hepatology, business.industry, Incidence, Incidence (epidemiology), Liver Neoplasms, Large series, Retrospective cohort study, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Middle Aged, Hepatocellular adenoma, medicine.disease, digestive system diseases, Tumor Burden, 3. Good health, Europe, Cell Transformation, Neoplastic, Cross-Sectional Studies, Treatment Outcome, 030220 oncology & carcinogenesis, Original Article, Female, Laparoscopy, 030211 gastroenterology & hepatology, business
Abstract

International audience; BACKGROUND:Hepatocellular adenoma (HCA) is a benign hepatic lesion that may be complicated by bleeding and malignant transformation. The aim of the present study is to report on large series of liver resections for HCA and assess the incidence of hemorrhage and malignant transformation.METHODS:A retrospective cross-sectional study, from 27 European high-volume HPB units.RESULTS:573 patients were analyzed. The female: male gender ratio was 8:2, mean age: 37 ± 10 years. Of the 84 (14%) patients whose initial presentation was hemorrhagic shock (Hemorrhagic HCAs), hemostatic intervention was urgently required in 25 (30%) patients. No patients died after intervention. Tumor size was >5 cm in 74% in hemorrhagic HCAs and 64% in non-hemorrhagic HCAs (p < 0.001). In non-hemorrhagic HCAs (n = 489), 5% presented with malignant transformation. Male status and tumor size >10 cm were the two predictive factors. Liver resections included major hepatectomy in 25% and a laparoscopic approach in 37% of the patients. In non-hemorrhagic HCAs, there was no mortality and major complications occurred in 9% of patients.DISCUSSION:Liver resection for HCA is safe. Presentation with hemorrhage was associated with larger tumor size. In males with a HCA >10 cm, a HCC should be suspected. In such situation, a preoperative biopsy is preferable and an oncological liver resection should be considered.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results